S565
Clinical – Head & neck
ESTRO 2026
recovery in mucosal and swallowing function by follow-up. These findings support the potential role of PBM as an adjunctive strategy to improve tolerance to treatment in head and neck cancer. References: Cruz R., et al. Efficacy of photobiomodulation therapy in the management of oral mucositis in patients with head and neck cancer: a systematic review and meta- analysis of randomized controlled trials. Head & Neck. 2024.Khalil M., et al. Effect of Photobiomodulation on Salivary Cytokines in Head and Neck Cancer Patients with Oral Mucositis: A Systematic Review. J Clin Med. 2024;13(10):2822.Photobiomodulation Therapy in the Treatment of Oral Mucositis, Dysphagia, Oral Dryness, Taste Alteration, and Burning Mouth Sensation Due to Cancer Therapy: A Case Series. J Lasers Med Sci. 2020;11(4):369-380. Keywords: Photobiomodulation, radiodermatitis, dysphagia Digital Poster 1341 Stronger Together: Prospective Clinical Trial of an Innovative Interdisciplinary Workflow for Treatment of Patients with Midface Tumors (NCT05671458) Lukas Bauer 1,2 , Reinald Kühle 3 , Jennifer Fuchs 3 , Julius Moratin 3 , Maximilian Deng 1,2 , Markus Ehle 1,2 , Philipp Schröter 1,2 , Florian Stritzke 1,2 , Rasmus Schindehütte 1,2 , Sebastian Adeberg 4,5 , Katharina Kozyra 1,2 , Thomas Welzel 1,2 , Amir Abdollahi 6,2 , Thomas Held 1,2 , Jürgen Hoffmann 3 , Jürgen Debus 1,2 , Sebastian Regnery 1,2 1 Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany. 2 Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg University Hospital, Heidelberg, Germany. 3 Department of Oral and Maxillofacial Surgery, Heidelberg University Hospital, Heidelberg, Germany. 4 Department of Radiotherapy and Radiation Oncology, Marburg University Hospital, Marburg, Germany. 5 Marburg Ion-Beam Therapy Center (MIT), Marburg University Hospital, Marburg, Germany. 6 Clinical Cooperation Unit Translational Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany Purpose/Objective: Midface tumors are often diagnosed at a locally advanced stage. Despite surgery followed by postoperative radiotherapy (PORT), local tumor progression remains common. Effective communication and coordination between disciplines appear to be essential factors influencing treatment outcomes. Therefore, this study investigates how an interdisciplinary workflow - based on advanced imaging and intraoperative navigation - improves the
Twenty-two patients were analyzed : 86% men and 14% women, with a median age at diagnosis of 57. Primary tumor sites included : oropharynx (54.5%), oral cavity (27.3%), nasopharynx (13.6%), and hypopharynx/larynx (4.5%). 95.5% received concurrent chemotherapy with weekly cisplatin (40 mg/m ² ) or cisplatin every three weeks (100 mg/m ² ). The mean number of PBM sessions was 19.5, and the mean cumulative radiotherapy dose was 68.7 Gy. Grade III– IV oral mucositis occurred in 4.5% at T1, 27.2% at T2, 59.1% at T3, and 0% at T4, while grade III–IV dysphagia was observed in 13.6%, 31.8%, 45.4%, and 9.0%, respectively. Severe radiodermatitis (grade III–IV) was rare (4.5% of patients at T3 only). The need for nutritional support increased from 13.6% at T1 to 31.8% at T2 and 59.1% at T3, before declining to 31.8% at T4. Strong opioid use was required in 4.5% of patients at T1, 18.2% at T2, 54.5% at T3, decreasing and 18.2% at T4. The visual analog scale (VAS) scores in the context of dysphagia demonstrated a mean value of 1.9 at T1, increasing to 3.0 at T2 and 3.6 at T3, before declining to 0.6 at T4, indicating effective pain management. Among the 10 patients who initially received cisplatin at 100 mg/m ² , 5 required a protocol modification to cisplatin 40 mg/m ² : one due to renal impairment, two due to hematologic toxicity, and two due to combined hematologic toxicity and malnutrition. No additional dose adjustment was observed. Conclusion: Daily PBM was associated with reduced chemoradiotherapy-related toxicities, with marked
Made with FlippingBook - Share PDF online